1. 390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors. (9th November 2020) Authors: Gillison, Maura; Cohen, Roger; Twardowski, Przemyslaw; Sukari, Ammar; Johnson, Melissa; Lackner, Rudy; Davis, Thomas; DeCillis, Arthur; Hernandez, Richard; Price, Jessica; Mancini, Kevin; Shainheit, Mara; Flechtner, Jessica; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A415 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors. (9th November 2020) Authors: Gillison, Maura; Cohen, Roger; Twardowski, Przemyslaw; Sukari, Ammar; Johnson, Melissa; Lackner, Rudy; Davis, Thomas; DeCillis, Arthur; Hernandez, Richard; Price, Jessica; Mancini, Kevin; Shainheit, Mara; Flechtner, Jessica; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗